Market Place
Sourcing Support
Saladax, HLS Strengthen Partnership With Distribution Agreement for Canada
18 Nov 2021 //
BUSINESSWIRE
HLS Therapeutics Announces Promotional Agreement with Pfizer for Vascepa
16 Aug 2021 //
NEWSWIRE
HLS Therapeutics Announces Second Quarter Fiscal 2021 Financial Results
05 Aug 2021 //
NEWSWIRE
HLS Therapeutics Comments on Rule Enacted by Quebec Health Minister
01 Apr 2021 //
NEWSWIRE
HLS Therapeutics Announces that Icosapent Ethyl (Vascepa®)
29 Mar 2021 //
NEWSWIRE
HLS Therapeutics Announces Fourth Quarter and Fiscal 2020 Financial Results
18 Mar 2021 //
CNW GROUP
HLS Therapeutics Provides Update on Private and Public Payer for Vascepa®
16 Feb 2021 //
NEWSWIRE
HLS Announces Update on Health Canada Filings for MyCare
16 Dec 2020 //
NEWSWIRE
HLS Therapeutics reports positive data from Covid-19 outpatient trial
15 Dec 2020 //
CLINICALTRIALSARENA
HLS Therapeutics Announces Health Canada Approval of PERSERIS®
17 Nov 2020 //
INVESTORROOM
HLS Therapeutics Highlights Latest Icosapent Ethyl Research
23 Oct 2020 //
PRESS RELEASE
HLS Therapeutics Acquires Portfolio of Four Royalty Interests
30 Sep 2020 //
NEWSWIRE
HLS Therapeutics welcomes both CADTH`s recommendation to reimburse Vascepa®
21 Jul 2020 //
INVESTORROOM
HLS Therapeutics welcomes both CADTH`s recommendation to reimburse Vascepa®
20 Jul 2020 //
NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.